In Re RIGGS

Plain English (For Everyone)

The court ruled that you cannot patent a method of using an existing FDA-approved drug for a new medical condition. This means that if a doctor discovers a new use for a common medication, they generally cannot get a patent for that specific method of treatment. The decision aims to prevent patents on natural discoveries rather than true inventions.

For Legal Practitioners

The Federal Circuit affirmed the PTAB's finding that claims directed to a method of treating a disease or condition with a drug approved for a different use are ineligible under 35 U.S.C. § 101 as abstract ideas and natural phenomena. The court found no inventive concept sufficient to transform the claims into patent-eligible subject matter, emphasizing that merely identifying a new therapeutic use for a known drug does not satisfy the § 101 requirements.

For Law Students

In re Riggs clarifies that methods of using known drugs for newly discovered therapeutic purposes are not patent-eligible under 35 U.S.C. § 101. The Federal Circuit classified these claims as directed to an abstract idea and a natural phenomenon, lacking the necessary inventive concept to overcome the judicial exceptions. This decision reinforces the distinction between patentable inventions and natural discoveries.

Newsroom Summary

A federal court has ruled that new uses for existing drugs cannot be patented if they are simply based on discovering a natural effect. The decision, in the In re Riggs case, means that medical breakthroughs involving repurposing medications for new conditions may not be eligible for patent protection, impacting innovation in drug development.

Standard of Review

De Novo review. The Federal Circuit reviews the Patent Trial and Appeal Board's (PTAB) eligibility determination under 35 U.S.C. § 101 without deference.

Procedural Posture

The case reached the Federal Circuit on appeal from the Patent Trial and Appeal Board (PTAB), which had determined that the claims at issue were not eligible for patent protection under 35 U.S.C. § 101.

Burden of Proof

The patent applicant bears the burden of proving that their claims are eligible for patent protection. The standard is whether the claims are directed to patent-eligible subject matter.

Legal Tests Applied

Statutory References

Key Legal Definitions

Rule Statements

Claims directed to the abstract idea of using a drug for a newly discovered therapeutic purpose are not patent-eligible under § 101.

A newly discovered therapeutic purpose is a natural phenomenon and thus falls within a judicial exception to patent eligibility.

To be patent-eligible, claims directed to a judicial exception must contain an inventive concept that transforms the claim into a patent-eligible application.

Remedies

Affirmed the PTAB's decision that the claims are not patent-eligible.

Scenario: A researcher discovers that an existing, FDA-approved drug for high blood pressure is also effective in treating a rare autoimmune disease.

Your Rights: You do not have the right to patent the method of using that specific drug to treat the autoimmune disease, as this is considered a discovery of a natural phenomenon and an abstract idea, not an invention.

What To Do: Focus on developing novel formulations, delivery methods, or combination therapies involving the drug, as these might be patentable. Alternatively, explore other forms of protection or market exclusivity if available.

Is it legal to patent a new use for an existing drug?

No, generally not. The Federal Circuit in In re Riggs held that methods claiming a newly discovered therapeutic use for an FDA-approved drug are not patent-eligible under 35 U.S.C. § 101 because they are directed to an abstract idea and a natural phenomenon without an inventive concept.

This ruling applies to patent law in the United States.

For Pharmaceutical Companies

Companies may find it harder to obtain patents for drug repurposing efforts, potentially reducing incentives for investing in discovering new uses for existing drugs. They may need to focus patent strategies on novel formulations, delivery systems, or combination therapies.

For Medical Researchers

Researchers who discover new therapeutic uses for existing drugs will likely not be able to patent these methods of treatment. This could affect their ability to secure funding or exclusive rights based on such discoveries.

For Patients

While potentially limiting exclusive market access for new uses of old drugs, this ruling could also lead to faster availability of treatments if companies are less focused on patenting simple repurposing methods and more on broad accessibility or alternative development paths.

Q: What is In Re RIGGS about?

In Re RIGGS is a case decided by Federal Circuit on March 24, 2025.

Q: What court decided In Re RIGGS?

In Re RIGGS was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was In Re RIGGS decided?

In Re RIGGS was decided on March 24, 2025.

Q: What is the citation for In Re RIGGS?

The citation for In Re RIGGS is . Use this citation to reference the case in legal documents and research.

Q: What was the main issue in In re Riggs?

The main issue was whether a method for treating a disease using an FDA-approved drug for a different condition was patent-eligible subject matter under 35 U.S.C. § 101. The Federal Circuit found it was not.

Q: Is In Re RIGGS published?

In Re RIGGS is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in In Re RIGGS?

The court ruled in favor of the defendant in In Re RIGGS. Key holdings: Methods of treating a disease or condition with a drug or biologic approved by the FDA for a different use are not patentable subject matter under 35 U.S.C. § 101, as they claim an abstract idea.; The court applied the Alice/Mayo framework, finding the claims were directed to the abstract idea of using a drug for a newly discovered therapeutic purpose.; The claims did not recite significantly more than the abstract idea itself, failing to transform the abstract idea into a patent-eligible application.; The mere discovery of a new therapeutic use for an existing drug, without more, does not render a method patent-eligible under § 101.; The court distinguished this case from prior decisions where patentable subject matter was found, emphasizing that the claims here were not tied to a specific diagnostic or treatment protocol that integrated the discovery..

Q: Why is In Re RIGGS important?

In Re RIGGS has an impact score of 75/100, indicating significant legal impact. This decision reinforces the Federal Circuit's strict interpretation of patent eligibility for diagnostic and treatment methods, particularly concerning 'off-label' uses of drugs. It signals that simply discovering a new therapeutic use for an existing drug, without more, is unlikely to be patentable subject matter. This could significantly impact the pharmaceutical industry's patenting strategies for drug repurposing.

Q: What precedent does In Re RIGGS set?

In Re RIGGS established the following key holdings: (1) Methods of treating a disease or condition with a drug or biologic approved by the FDA for a different use are not patentable subject matter under 35 U.S.C. § 101, as they claim an abstract idea. (2) The court applied the Alice/Mayo framework, finding the claims were directed to the abstract idea of using a drug for a newly discovered therapeutic purpose. (3) The claims did not recite significantly more than the abstract idea itself, failing to transform the abstract idea into a patent-eligible application. (4) The mere discovery of a new therapeutic use for an existing drug, without more, does not render a method patent-eligible under § 101. (5) The court distinguished this case from prior decisions where patentable subject matter was found, emphasizing that the claims here were not tied to a specific diagnostic or treatment protocol that integrated the discovery.

Q: What are the key holdings in In Re RIGGS?

1. Methods of treating a disease or condition with a drug or biologic approved by the FDA for a different use are not patentable subject matter under 35 U.S.C. § 101, as they claim an abstract idea. 2. The court applied the Alice/Mayo framework, finding the claims were directed to the abstract idea of using a drug for a newly discovered therapeutic purpose. 3. The claims did not recite significantly more than the abstract idea itself, failing to transform the abstract idea into a patent-eligible application. 4. The mere discovery of a new therapeutic use for an existing drug, without more, does not render a method patent-eligible under § 101. 5. The court distinguished this case from prior decisions where patentable subject matter was found, emphasizing that the claims here were not tied to a specific diagnostic or treatment protocol that integrated the discovery.

Q: What cases are related to In Re RIGGS?

Precedent cases cited or related to In Re RIGGS: Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).

Q: What did the court decide about patenting new uses for existing drugs?

The court decided that discovering a new therapeutic use for an existing drug, especially one already approved by the FDA, is not patentable. This is because such claims are considered directed to an abstract idea and a natural phenomenon.

Q: Why are these methods not patentable?

The court reasoned that the claims were directed to the abstract idea of using a drug for a newly discovered therapeutic purpose, which is considered a natural phenomenon. The claims lacked an 'inventive concept' to transform this discovery into a patent-eligible application.

Q: What is 35 U.S.C. § 101?

35 U.S.C. § 101 is the U.S. patent statute that defines what types of inventions are eligible for patent protection, including processes, machines, manufactures, and compositions of matter.

Q: What is an 'abstract idea' in patent law?

An abstract idea is a fundamental concept or method of organizing human activity that is not tied to a specific machine or transformation. The court in In re Riggs found the method of using a drug for a new therapeutic purpose to be an abstract idea.

Q: What is a 'natural phenomenon' in patent law?

A natural phenomenon is something that exists in nature and is not the product of human invention, such as laws of physics or natural processes. The court considered the newly discovered therapeutic effect of a drug to be a natural phenomenon.

Q: What is an 'inventive concept'?

An inventive concept is an additional element or combination of elements in a patent claim that transforms a claim directed to a judicial exception (like an abstract idea or natural phenomenon) into a patent-eligible application.

Q: Does this ruling apply to all drug patents?

No, this ruling specifically applies to methods of treatment that claim a newly discovered therapeutic use for an existing drug. It does not affect patents on new chemical entities, novel formulations, or new delivery systems.

Q: How does In Re RIGGS affect me?

This decision reinforces the Federal Circuit's strict interpretation of patent eligibility for diagnostic and treatment methods, particularly concerning 'off-label' uses of drugs. It signals that simply discovering a new therapeutic use for an existing drug, without more, is unlikely to be patentable subject matter. This could significantly impact the pharmaceutical industry's patenting strategies for drug repurposing. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: What should I do if I discover a new use for an existing drug?

You generally cannot patent the method of using the drug for that new purpose. You should consult with a patent attorney to explore if other aspects, like a specific formulation or combination therapy, might be patentable.

Q: How does this affect pharmaceutical companies?

It makes it more difficult to patent drug repurposing discoveries, potentially impacting investment strategies. Companies may need to focus on patenting novel aspects beyond just the new use itself.

Q: Can I still get a patent for a completely new drug?

Yes, the discovery and invention of a new chemical compound with a useful purpose is generally patentable, provided it meets other patentability requirements like novelty and non-obviousness.

Q: What is the history of patent eligibility for medical treatments?

Patent eligibility for medical treatments has evolved through various court decisions, with recent focus on distinguishing patentable inventions from natural phenomena and abstract ideas, particularly following the Supreme Court's decisions in Alice Corp. and Mayo Collaborative Services.

Q: What was the docket number in In Re RIGGS?

The docket number for In Re RIGGS is 22-1945. This identifier is used to track the case through the court system.

Q: Can In Re RIGGS be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: How did the PTAB rule before the Federal Circuit?

The Patent Trial and Appeal Board (PTAB) had previously determined that the claims in In re Riggs were not eligible for patent protection under 35 U.S.C. § 101, finding them directed to an abstract idea.

Q: What is the standard of review for patent eligibility decisions?

The Federal Circuit reviews a PTAB's determination of patent eligibility under 35 U.S.C. § 101 de novo, meaning they look at the issue fresh without giving deference to the PTAB's prior decision.